lilly retatrutide ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide Helped Adults With Obesity

Endocrinology , 166 (2), bqae165

Biomarker assessment may provide objective measures of treatment efficacy and neurological recovery

This study showed that the risk of recurrent pancreatitis in a cohort of patients taking GLP-1 receptor agonists (10%) was likely no greater than what is observed in the general population and that more than half of the episodes of recurrent pancreatitis were attributable to causes other than GLP-1 receptor agonist therapy

Cost, Access, and Daily Experience Cost comparison favors Contrave in some cases

Plaintiffs allege that Novo Nordisk, the drugs manufacturer, did not adequately warn users and healthcare providers about these risks

Thank you Revenge MD